Targeting PIF1 by chemical inhibition or genetic modification in BRCA2-deficient MBs could allow for selective killing of tumor cells, sparing surrounding normal cerebellum that lacks Pif1 expression. The gene discussed is BRCA2; the disease is Mobius syndrome.